Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Benitec Biopharma Inc. before investing.

In this article, we go over a few key elements for understanding Benitec Biopharma Inc.’s stock price such as:

• Benitec Biopharma Inc.’s current stock price and volume
• Why Benitec Biopharma Inc.’s stock price changed recently
• Upgrades and downgrades for BNTC from analysts
• BNTC’s stock price momentum as measured by its relative strength

About Benitec Biopharma Inc. (BNTC)

Before we jump into Benitec Biopharma Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Want to learn more about Benitec Biopharma Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Benitec Biopharma Inc..

Benitec Biopharma Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Benitec Biopharma Inc.’s stock price was $11.710.

Benitec Biopharma Inc. is down 1.26% from its previous closing price of $11.860.

During the last market session, Benitec Biopharma Inc.’s stock traded between $11.110 and $11.910. Currently, there are approximately 49.39 million shares outstanding for Benitec Biopharma Inc..

Benitec Biopharma Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Benitec Biopharma Inc. Stock Price History

Benitec Biopharma Inc.’s (BNTC) price is currently down 12.48% so far this month.

During the month of July, Benitec Biopharma Inc.’s stock price has reached a high of $13.840 and a low of $11.100.

Over the last year, Benitec Biopharma Inc. has hit prices as high as $16.760 and as low as $9.850. Year to date, Benitec Biopharma Inc.’s stock is down 13.07%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Benitec Biopharma Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were analysts who downgraded Benitec Biopharma Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Benitec Biopharma Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Benitec Biopharma Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Benitec Biopharma Inc. (BNTC) by visiting AAII Stock Evaluator.

Relative Price Strength of Benitec Biopharma Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Benitec Biopharma Inc. has a weighted four-quarter relative price strength of -1.17%, which translates to a Momentum Score of 48 and is considered to be Average.

Want to learn more about how Benitec Biopharma Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Benitec Biopharma Inc. Stock Price: Bottom Line

As of July 31, 2026, Benitec Biopharma Inc.’s stock price is $11.710, which is down 1.26% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Benitec Biopharma Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.